Celldex Therapeutics, Inc.CLDXEarnings & Financial Report
Nasdaq
NextMar 30, 2026
CLDX Q3 2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-73.6M
Net Profit
$-67.0M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-1.01
Celldex Therapeutics, Inc. Q3 2025 Financial Summary
Celldex Therapeutics, Inc. reported revenue of $0 for Q3 2025, with a net profit of $-67.0M (N/A margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-67.0M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 2025 |
Celldex Therapeutics, Inc. Annual Revenue by Year
Celldex Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $7.0M).
| Year | Annual Revenue |
|---|---|
| 2024 | $7.0M |
| 2023 | $6.9M |
| 2022 | $2.4M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.1M | $156000 | $2.5M | $3.2M | $1.2M | $695000 | $730000 | $0 |
| YoY Growth | 156.1% | -83.9% | 832.1% | 110.3% | -71.6% | 345.5% | -70.8% | N/A |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $465.6M | $868.8M | $845.6M | $823.2M | $792.3M | $739.5M | $692.4M | $648.4M |
| Liabilities | $36.5M | $30.2M | $31.9M | $37.3M | $45.3M | $36.5M | $37.0M | $50.1M |
| Equity | $429.2M | $838.6M | $813.7M | $785.9M | $747.0M | $703.0M | $655.4M | $598.4M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-32.5M | $-40.6M | $-29.3M | $-55.3M | $-32.5M | $-54.4M | $-44.0M | $-48.6M |